Skip to main content
Erschienen in: Supportive Care in Cancer 12/2009

01.12.2009 | Original Article

Prevalence of emotional distress in newly diagnosed lung cancer patients

verfasst von: Tracy Steinberg, Michelle Roseman, Goulnar Kasymjanova, Sarah Dobson, Lucie Lajeunesse, Esther Dajczman, Harvey Kreisman, Neil MacDonald, Jason Agulnik, Victor Cohen, Zeev Rosberger, Martin Chasen, David Small

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Distress is defined by the National Comprehensive Cancer Network as a multifactorial unpleasant emotional experience of a psychological, social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer. We investigated the prevalence and associated symptoms of distress in newly diagnosed lung cancer patients.

Patients and methods

Between November 2005 and July 2007, 98 newly diagnosed lung cancer patients completed an assessment. The Distress Thermometer (DT) and Edmonton Symptom Assessment Scale (ESAS) were used as screening tools.

Main results

Fifty (51%) patients reported clinically significant distress (≥4) on the DT. Of those, 26 (52%) patients reported high levels of depression, nervousness, or both on ESAS. The remaining 24 (48%) patients had elevated levels of distress but no significant depression or nervousness. A correlation between the DT and the total ESAS score was observed (Pearson correlation = 0.46). The ten items of the ESAS together explained 46% of the variability in DT scores. The depression and nervousness ESAS items were significant predictors of DT score (p < 0.01 for both items). However, once the two psychosocial items, depression and nervousness, were removed from the total ESAS score, leaving only physical symptoms and the sleeplessness item, the predictive power of the model decreased to R² = 0.12.

Conclusions

The prevalence of distress in lung cancer patients is high. The DT appears to discriminate between physical and emotional distress. This easily measured score may determine which patients require further intervention for emotional distress.
Literatur
3.
Zurück zum Zitat World Health Organization International Agency for Research on Cancer (IARC) (2008) World Cancer Report. IARC, Lyon World Health Organization International Agency for Research on Cancer (IARC) (2008) World Cancer Report. IARC, Lyon
4.
Zurück zum Zitat National Comprehensive Cancer Network. NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. 2008. National Comprehensive Cancer Network. NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. 2008.
6.
7.
Zurück zum Zitat Holland J, Bultz B (2007) The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw 5(1):3–7PubMed Holland J, Bultz B (2007) The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw 5(1):3–7PubMed
10.
Zurück zum Zitat Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
13.
Zurück zum Zitat Philip J et al (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6(6):539–541. doi:10.1007/s005200050212 CrossRefPubMed Philip J et al (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6(6):539–541. doi:10.​1007/​s005200050212 CrossRefPubMed
Metadaten
Titel
Prevalence of emotional distress in newly diagnosed lung cancer patients
verfasst von
Tracy Steinberg
Michelle Roseman
Goulnar Kasymjanova
Sarah Dobson
Lucie Lajeunesse
Esther Dajczman
Harvey Kreisman
Neil MacDonald
Jason Agulnik
Victor Cohen
Zeev Rosberger
Martin Chasen
David Small
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0614-6

Weitere Artikel der Ausgabe 12/2009

Supportive Care in Cancer 12/2009 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.